Lu Luo

Lu Luo

Auto-generated profile, based on publicly available information

Lu Luo

Reproductive Medicine Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Human Reproduction
Verified
Journal Article
Closed access
CWCan Wang
Can Wang
YLYouhui Lu
Youhui Lu
MOMiaoxian Ou
Miaoxian Ou
LQLingxuan Qian
Lingxuan Qian
YZYingying Zhang
Yingying Zhang
QWQiong Wang
Qiong Wang
STUDY QUESTION: What are the unrecognized risk factors for recurrent implantation failure (RIF) as defined in the ESHRE recommendation? SUMMARY ANSWER: Anti-Müllerian hormone (AMH) is the strongest predictor for RIF, followed by chronic endometritis (CE), intrauterine adhesions, and BMI. WHAT IS KNOWN ALREADY: Advanced age is a well-known risk factor for implantation failure, and the definition of RIF was stratified by age in the 2023 ESHRE recommendation. However, the literature identifies other risk factors, including CE, endometriosis, BMI, endometrial polyps, intrauterine adhesions, hydrosalpinx, uterine malformation, submucosal myoma, polycystic ovary syndrome, thyroid dysfunction, rheumatic diseases, and hyperprolactinemia, to be associated with implantation failure. In addition, our clinical experience suggests AMH and a history of previous livebirth affect RIF. It remains unclear which of these factors are the best predictors of RIF. STUDY DESIGN, SIZE, DURATION: A cohort study drawn from ART cycles between June 2019 and June 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Two hundred and ninety-eight RIF patients and 2056 controls (women who achieved successful embryo implantation within 1–2 transfer cycles) were identified from 15 329 ART cycles at the Reproductive Medical Center at the First Affiliated Hospital of Sun Yat-sen University. RIF was defined according to the recommendation of ESHRE 2023. Basic characteristics, reproductive history, laboratory indicators (autoantibodies and endocrine factors), ultrasound, laparoscopy, hysteroscopy, hysterosalpingography, biopsy, and immunohistochemistry results were collected from the electronic medical record system. The Random Forest procedure was applied to build a machine learning model for predicting RIF. Overall predictive accuracy was assessed by using the AUC of receiver–operator characteristic curve and calibration plots. The SHapley Additive exPlanations (SHAP) framework was used to interpret the model. MAIN RESULTS AND THE ROLE OF CHANCE: From 32 variables, elevated AMH level and greater number of live births were associated with lower risk of RIF, while CE, intrauterine adhesions, high FSH level, high testosterone level, advanced female age, polyps, history of recurrent pregnancy loss, history of cesarean section, polycystic ovary syndrome, and rheumatic diseases were associated with higher risk of RIF according to the established random forest model. The predictive model yielded AUCs of 0.83 (95% CI: 0.80–0.86) in training dataset and 0.78 (95% CI: 0.73–0.84) in testing dataset. The calibration curve indicated good predictive performance in both training and testing datasets. SHAP values indicated that AMH had the greatest influence on the RIF risks, whereas CE, intrauterine adhesions, and BMI were the second, third, and fourth most significant risk factors for predicting RIF, respectively. LIMITATIONS, REASONS FOR CAUTION: This research was limited by its retrospective design from a single reproductive medical center. Moreover, some diseases, such as polyps, submucosal myomas, and rheumatic diseases, had been treated before ART, which indicates that these factors impact RIF even after treatment. WIDER IMPLICATIONS OF THE FINDINGS: In addition to age, certain high-risk factors, such as AMH, should also be included in the considerations for RIF. Patients with a combination of these high-risk factors may require more attempts to achieve a successful pregnancy. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Guangzhou Municipal Science and Technology Project under Grant (202206010003) and the National Natural Science Foundation of China under Grant (81871159). None of the authors has any conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

13 May 2019 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
LLLu Luo
Lu Luo
XFXiong‐Zhi Fan
Xiong‐Zhi Fan
HJHui‐Ying Jie
Hui‐Ying Jie
YGYong Gao
Yong Gao
MCMinghui Chen
Minghui Chen
QWQiong Wang
Qiong Wang

1 October 2025 in Reproduction and Fertility
Verified
Journal Article
Open access
YYYuxin Yang
Yuxin Yang
XZXiaoran Zhang
Xiaoran Zhang
YZYingying Zhang
Yingying Zhang
MOMiaoxian Ou
Miaoxian Ou
CWCan Wang
Can Wang
QWQiong Wang
Qiong Wang
This prospective cohort study aimed to assess whether a history of embryonic chromosomal abnormality affects subsequent pregnancy outcomes in women with unexplained recurrent pregnancy loss. A total of 233 women with unexplained recurrent pregnancy loss who conceived naturally were included. Participants were categorized according to the chromosomal status of prior miscarriages. A multivariate logistic regression model was constructed to predict live birth based on these categories and observed pregnancy outcomes. Among the 233 included women, 171 (73.4%) had a live birth, while 62 (26.6%) experienced early pregnancy loss. Among women with one abnormal chromosomal miscarriage (n = 110), 94 (85.5%) had a live birth, accounting for 40.3% of the total cohort. In contrast, in the one normal chromosomal miscarriage group (n = 77), 47 (61.0%) achieved live birth, representing 20.2% of the total. The model identified a history of one chromosomally abnormal miscarriage (odds ratio = 3.88, 95% confidence interval: 1.87–8.06) and history of two chromosomally abnormal miscarriages (odds ratio = 8.93, 95% confidence interval: 1.07–74.55) as significant predictors of live birth. The predictive model achieved an area under the curve of 0.73 in the training dataset and 0.75 in the testing dataset. A history of embryonic chromosomal miscarriage may reflect improved pregnancy prospects and inform clinical counseling in unexplained recurrent pregnancy loss. Lay summary: Women with unexplained recurrent miscarriage often wonder whether their history will affect future natural pregnancies. Chromosomal abnormalities in embryos are a leading cause of miscarriage, but the impact of such a history on later outcomes has remained unclear. We studied 233 women with repeated unexplained losses and assessed their subsequent pregnancy results. Overall, 73.4% achieved a live birth, while 26.6% had another early miscarriage. Interestingly, among women who had one chromosomal abnormal miscarriage, 85.5% subsequently achieved a live birth. In contrast, the live birth rate was lower in the group who had a normal chromosomal miscarriage; only 61.0% went on to achieve a live birth. These results suggest that a history of abnormal chromosomal miscarriage may indicate better chances of future pregnancy and help guide clinical care.

16 March 2023 in AJOG Global Reports
Verified
Journal Article
Open access
HJHui-Ying Jie
Hui-Ying Jie
RHRuifang Hu
Ruifang Hu
LZLimei Zhang
Limei Zhang
KDKexin Dong
Kexin Dong
CWChunyan Wu
Chunyan Wu
LLLu Luo
Lu Luo
Recent studies have reported higher risks of adverse maternal and neonatal outcomes, such as hypertensive disorders of pregnancy, after programmed frozen embryo transfer, especially in cycles with gonadotropin-releasing hormone agonist pretreatment. It remains unclear if GnRH agonist pretreatment before programmed frozen embryo transfer further increases the risk for obstetrical complications among women with polycystic ovary syndrome. This study aimed to compare the obstetrical and neonatal complications of singleton and twin pregnancies after programmed frozen embryo transfer with or without gonadotropin-releasing hormone-a pretreatment among women with polycystic ovary syndrome. This was a secondary analysis of a single-center, randomized controlled trial comparing the live birth rate and cost-effectiveness of programmed cycle-prepared frozen embryo transfers with or without gonadotropin-releasing hormone agonist pretreatment among women with polycystic ovary syndrome. The analysis was restricted to women with polycystic ovary syndrome, aged 24 to 40 years, who delivered live neonates after frozen-thawed blastocyst transfer. The obstetrical and neonatal outcomes were compared between programmed cycles with and those without gonadotropin-releasing hormone agonist pretreatment. The adjusted odds ratios with 95% confidence intervals were calculated and adjustments were made for relevant confounders. The maternal and neonatal complications associated with 177 live single births and 38 twin births (253 newborns in total) were analyzed. There were no significant differences in the frequencies of obstetrical complications, including hypertensive disorders of pregnancy, between the gonadotropin-releasing hormone agonist pretreatment and no pretreatment group for both singleton and twin pregnancies. However, there was a significantly greater incidence of having a low birthweight neonate among singleton infants born after gonadotropin-releasing hormone agonist pretreatment when compared with no pretreatment (10.2% vs 1.3%; P=0.042), and a low birthweight among singleton infants was still more likely after adjusting for confounders (relative ratio, 3.85; 95% confidence interval, 1.13−7.11; P=.024). Other neonatal complications were all comparable between the pretreatment and no pretreatment groups for both singleton and twin pregnancies. For women with polycystic ovary syndrome, programmed frozen embryo transfer cycles with gonadotropin-releasing hormone agonist pretreatment could lead to a greater risk of having a low birthweight singleton neonate.

27 August 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
CWChunyan Wu
Chunyan Wu
RLRuochun Lian
Ruochun Lian
SZSuhua Zou
Suhua Zou
YXYan Xu
Yan Xu
YZYong Zeng
Yong Zeng
LLLu Luo
Lu Luo
Introduction: This study evaluated the effectiveness and cost-effectiveness of preimplantation genetic testing for aneuploidy (PGT-A) versus expectant management (EM) for achieving live birth among fertile patients with recurrent pregnancy loss (RPL) and prior aneuploid pregnancy loss. Methods: This dual-center retrospective cohort study included 216 fertile patients with RPL and at least one previous aneuploid pregnancy loss. Seventy-one patients chose EM and 145 chose PGT-A. Propensity score matching (PSM), multivariable logistic regression, and subgroup analyses were performed. The primary outcome was conception leading to live birth (CLLB) within 12 months. Secondary outcomes included CLLB at 24 and 36 months, cumulative live birth (CLB) at 5 years, time to pregnancy leading to live birth (TPLB), early miscarriage per clinical pregnancy, and incremental cost-effectiveness ratios (ICERs). Results: After PSM, 71 matched pairs were analyzed. CLLB within 12 months was lower in the PGT-A group than in the EM group (52.1% vs. 81.7%; adjusted odds ratio 0.27, 95% confidence interval 0.13–0.53; P < 0.001). Five-year CLB rates were similar (94.4% vs. 87.3%; P = 0.15), whereas TPLB was longer with PGT-A (median 8.6 vs. 3.0 months; P < 0.001). Early miscarriage rates per clinical pregnancy did not differ significantly (7.4% vs. 12.4%; adjusted odds ratio 0.42; P = 0.09). The ICERs per additional live birth and per miscarriage prevented were ¥1,203,800 and ¥1,504,800, respectively. Discussion: In fertile patients with RPL and prior aneuploidy, PGT-A and EM were associated with similar 5-year cumulative live birth rates, whereas EM was associated with a higher probability of CLLB within 12 months and a shorter TPLB. A possible reduction in miscarriage with PGT-A remains uncertain and warrants further investigation.

28 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
YCYixin Chen
Yixin Chen
TYTurui Yang
Turui Yang
ZLZicong Luo
Zicong Luo
LLLu Luo
Lu Luo
ZZZiqing Zhang
Ziqing Zhang
MCMinghui Chen
Minghui Chen
Background: Polycystic ovary syndrome (PCOS) is characterized by substantial inter-individual variability in ovarian sensitivity to recombinant follicle-stimulating hormone (rFSH) during controlled ovarian stimulation (COS). Clinically applicable tools for personalized dosing in this population remain limited. Methods: This retrospective single-center study (2013–2024) analyzed 369 PCOS patients undergoing GnRH antagonist protocols who achieved optimal ovarian responses (10–20 oocytes with at least 40% of follicles ≥ 16 mm in diameter on trigger day). The final retrospective dataset was randomly split into modeling (n = 258) and validation (n = 111) groups. A multivariate linear regression model incorporating age, BMI, basal FSH, basal LH, AMH, and AFC was developed to estimate the average daily rFSH dose. Model performance was evaluated using correlation analysis, prediction error metrics, and calibration assessment. Results: Age, BMI, and basal FSH were positively associated with average daily rFSH dose, whereas basal LH, AMH, and AFC were negatively associated. The model explained 40.4% of the variability in average daily rFSH dose. In the modeling cohort, 77.9% of estimated doses fell within ±20% of the observed values, with a moderate correlation between predicted and observed doses (ρ = 0.646). In the validation cohort, 67.6% of estimates met the predefined accuracy threshold (ρ = 0.676). Calibration analyses demonstrated robust agreement between predicted and observed doses. Conclusions: By integrating endocrine markers, ovarian reserve indicators, and clinical characteristics, this study provides a practical example of personalized medicine in COS in women with PCOS. The internally validated approach may support individualized rFSH dosing during COS and serve as a basis for future development of decision support tools in this specific population.